Prab: CSV import

2025-02-18T00:58:30Z

CSV import

← Older revision		Revision as of 00:58, 18 February 2025
Line 18:		Line 18:
	{{chelators}}		{{chelators}}
	{{coststubd}}		{{coststubd}}
			== Deferoxamine ==
			<gallery>
			File:Deferoxamine-2D-skeletal.png\|2D Skeletal Structure of Deferoxamine
			File:Deferoxamine-3D-vdW.png\|3D Van der Waals Model of Deferoxamine
			File:Chlorproethazine_synthesis.svg\|Synthesis of Chlorproethazine
			</gallery>

Prab: Created page with "{{intro}} Deferoxamine is a parenterally administered iron chelating agent used to treat transfusion related chronic iron overload. {{livtox}} Deferoxamine rarely causes ..."

2019-05-05T23:52:11Z

Created page with "{{intro}} Deferoxamine is a parenterally administered iron chelating agent used to treat transfusion related chronic iron overload. {{livtox}} Deferoxamine rarely causes ..."

New page

{{intro}}
Deferoxamine is a parenterally administered iron chelating agent used to treat transfusion related chronic iron overload.

{{livtox}}
Deferoxamine rarely causes serum aminotransferase elevations during therapy and has not been convincingly linked to instances of clinically apparent liver injury.

{{moa}}
Deferoxamine (de” fer ox’ a meen) is parenterally administered iron chelating agent that binds iron with a high affinity and zinc and copper to a lesser extent. In clinical trials in patients with transfusion related iron overload, deferoxamine therapy lowered both circulating and tissue (cardiac, liver) iron levels and these reductions were maintained with long term subcutaneous infusions.

{{fda}}
Deferoxamine was approved for use in the United States in 1968 and current indications are for patients with transfusion related chronic iron overload as well as for acute iron overdose or intoxication.

{{dose}}
Deferoxamine is available in vials of 500 and 2000 mg for intravenous, intramuscular or subcutaneous administration generically and under the brand name Desferal. The subcutaneous routine is used most often for chronic iron overload and the typical dose is 1000 to 2000 mg per day (20 to 40 mg/kg/day) for 5 to 7 days a week given by continuous infusion over 8 to 24 hours.

{{se}}
Side effects include injection site pain and infection, [[hypersensitivity reactions]], [[arthralgias]], [[myalgias]], [[fever]], [[headache]], [[nausea]] and [[abdominal pain]]. Rare, but potentially severe adverse events of deferoxamine therapy include hearing and visual loss, acute renal failure and severe hypersensitivity reactions.
{{chelators}}
{{coststubd}}

Deferoxamine - Revision history

Prab: CSV import

Prab: Created page with "{{intro}} Deferoxamine is a parenterally administered iron chelating agent used to treat transfusion related chronic iron overload. {{livtox}} Deferoxamine rarely causes ..."